
Test Update: COVID-19 IgG Antibody Testing Now Offered In-House

Date: May 15, 2020

Dear Regional Pathology Services Clients,

We are very excited to announce that we will begin offering in-house antibody testing for COVID-19 effective immediately. This test will replace the COR2G antibody test that was sent to our reference laboratory. COR2G will remain active until May 26, 2020.

Our clinical microbiology laboratory will begin offering a chemiluminescent immunoassay for the qualitative detection of IgG antibodies directed against SARS-CoV-2. The antigens used in this assay include both the S1 and S2 subunits of the coronavirus spike (S) glycoprotein, which facilitates entry into host cells.

The literature and our internal data suggest that IgG is reliably produced ~14 days following acute SARS-CoV-2 acute infection. Preliminary results from the FDA EUA studies and our own validation suggest that this assay does not detect IgG against circulating seasonal coronaviruses.

In addition, note this assay does not detect IgM and should not be used to diagnose acute disease. At this time, it is unclear if circulating IgG provides lasting immunity against COVID and thus detection of IgG against S1/S2 does not necessarily imply that an individual is immune. However, this assay will be a critical tool to assess SARS-CoV-2 antibody seroprevalence.

Specimens will be tested daily/all shifts

Specimen source: Human serum and plasma (Gold SST, sodium heparin, lithium heparin, and potassium EDTA)

Interpretation: Resulted as Negative or Positive

Test Name: SARS-CoV-2 IgG Antibody

Test Code: SAR2G

More information about this test can be found at <https://www.testmenu.com/nebraska/Tests/1041748>

Interface Build:

<u>OrderCode</u>	<u>OrderName</u>	<u>ResultCode</u>	<u>ResultName</u>	<u>LOINC</u>	<u>CPT</u>
SAR2G	SARS COV 2 IGG ANTIBODY	SAR2G	SARS COV 2 IGG ANTIBODY	94563-4	86769

If you have any questions about the interface build please contact **Interface**

Support: rpsinterfacesupport@unmc.edu.